Literature DB >> 31895949

Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis.

Alexandra E Dittrich1, Reed Taylor Sutton1, Kate Haynes1, Haili Wang2, Richard N Fedorak1, Karen I Kroeker1.   

Abstract

BACKGROUND: Many Crohn's disease (CD) patients will undergo surgery over the course of their life. It is thought that with the introduction of disease-modifying agents like anti-TNF therapy, there would be a population-level decrease in the need for surgery. This time-trend study aimed to assess the changes in surgical rates following the induction of anti-TNF therapy.
METHODS: Adult CD patients who underwent abdominal surgery (identified by administrative coding) between January of 1996 and December of 2013 at 1 of the 4 Edmonton-area hospitals were included. Patient charts were manually reviewed to confirm diagnosis and gather demographic and disease-related data. Population-adjusted annual incidence rates for IBD surgery were calculated by dividing the number of surgeries by estimates for total population of CD patients in Edmonton. Time-trend analysis was conducted to identify change points, calculate annual percent change (APC), and associated 95% confidence intervals (CIs).
RESULTS: A total of 1410 patients with Crohn's disease underwent surgery for their disease. The surgical rate decreased by 8.4% each year (95% CI, -9.6% to -7.3%). There was a 36.2% increase in the use of anti-TNF therapy per year (95% CI, 31.3% to 41.5%). Changes in modifiable risk factors for surgery were also seen, including the proportion of active smokers decreasing by 2.2% per year (95% CI, -3.7% to -0.6%).
CONCLUSIONS: Although anti-TNF therapy seems to play a role, the decrease in surgical trends is likely multifactorial, owing to a decline in smoking trends, earlier diagnosis, earlier treatment, improved patient education, and changes in clinical practice.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; biologic therapy; inflammatory bowel disease; surgery; time-trend study

Year:  2020        PMID: 31895949     DOI: 10.1093/ibd/izz315

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  5 in total

1.  Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.

Authors:  Rocio Sedano; Christopher Ma; Vipul Jairath; Brian G Feagan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-01

Review 2.  Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

Review 3.  Dietary Management of Chronic Kidney Disease and Secondary Hyperoxaluria in Patients with Short Bowel Syndrome and Type 3 Intestinal Failure.

Authors:  Maciej Adler; Ewen C Millar; Kevin A Deans; Massimo Torreggiani; Francesca Moroni
Journal:  Nutrients       Date:  2022-04-14       Impact factor: 6.706

4.  Usefulness of colestimide for diarrhea in postoperative Crohn's disease.

Authors:  Aya Hojo; Taku Kobayashi; Mao Matsubayashi; Hiromu Morikubo; Yusuke Miyatani; Tomohiro Fukuda; Kunio Asonuma; Shintaro Sagami; Masaru Nakano; Takahisa Matsuda; Toshifumi Hibi
Journal:  JGH Open       Date:  2022-07-14

5.  Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.

Authors:  Bharati D Kochar; Winston Cai; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2021-05-01       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.